VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

M. bovis WAg522 strain
Vaccine Information
  • Vaccine Name: M. bovis WAg522 strain
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0000557
  • Type: Attenuated vaccine
  • Antigen: The antigen for this vaccine was an attenuated strain of M. bovis called WAg522 (De et al., 1999).
  • Preparation: WAg522 is the second of four M. bovis mutants selected from 440 illegitimate recombinant M. bovis mutants via their inability to grow in minimal medium (De et al., 1999).
  • Virulence: This strain, along with the other tested M. bovis mutants in (De et al., 1999), was shown to be avirulent in guinea pigs following subcutaneous inoculation. Furthermore, the groups treated with WAg522 and WAg520 strains both showed significant differences in lung CFU versus nonvaccinated groups.
Host Response

Guinea pig Response

  • Host Strain: Duncan-Hartley
  • Vaccination Protocol: Four to eight guinea pigs per group were vaccinated by subcutaneous injection with 105 CFU with one of the four impaired M. bovis strains or BCG. Ten animals were not vaccinated (control) (De et al., 1999).
  • Side Effects: No delayed-type hypersensitivity reactions observed prior to inoculation with mycobacteria (De et al., 1999). Authors were unable to determine if nutritionally-impaired mutants influenced the development of necrotizing lesions in the lungs (De et al., 1999).
  • Challenge Protocol: All animals were anesthetized eight weeks post-vaccination via intramuscular injection with 3 mg ketamine hydrochloride, followed by 10x2 CFU virulent M. bovis WAg201 introduced through mouth into the trachea via cannula. Three guinea pigs which were not challeged received 105 CFU of each of the four strains via subcutaneous innoculation (De et al., 1999).
  • Efficacy: Significant differences in lung CFU were observed between vaccinated groups and WAg520 & WAg522 strains (De et al., 1999). WAg520 elicited 0.92, 3.83, and 2.47 log10 increases in lung, splenic, and liver tissues, respectively (see Table I, (De et al., 1999)). Macroscopic lesions were decreased in WAg520 recipients versus both non-vaccinated (significant different) and BCG-vaccinated (not significantly different) animals (see Table 2, (De et al., 1999)).
References
De et al., 1999: De Lisle GW, Wilson T, Collins DM, Buddle BM. Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis. Infection and immunity. 1999 May; 67(5); 2624-6. [PubMed: 10225931 ].